{"id":451381,"date":"2021-03-04T16:33:19","date_gmt":"2021-03-04T21:33:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451381"},"modified":"2021-03-04T16:33:19","modified_gmt":"2021-03-04T21:33:19","slug":"viking-therapeutics-to-participate-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/","title":{"rendered":"Viking Therapeutics to Participate at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p \/>\n<p \/>\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">March 4, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate in three upcoming investor conferences.\u00a0 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" title=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" alt=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Details of the company&#8217;s participation are as follows:<\/p>\n<ul type=\"disc\">\n<li>\n          <b>HC Wainwright Global Life Science Conference<br \/><\/b>Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings <br \/>Conference dates: <span class=\"xn-chron\">March 9-10, 2021<\/span><br \/>Presentation Timing: Available online at <span class=\"xn-chron\">7:00 a.m.<\/span> Eastern on <span class=\"xn-chron\">Tuesday, March 9, 2021<\/span><br \/>Format: Virtual conference; webcast available <\/li>\n<li>\n          <b>33<sup>rd<\/sup> Annual Roth Conference<br \/><\/b>Details: Viking management will participate in 1-on-1 meetings<br \/>Conference Date: <span class=\"xn-chron\">March 15-17<\/span>, 2021\u00a0<br \/>Format: Virtual Conference <\/li>\n<li>\n          <b>Oppenheimer&#8217;s 31<sup>st<\/sup> Annual Healthcare Conference<br \/><\/b>Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings <br \/>Conference Date: <span class=\"xn-chron\">March 16-18, 2021<\/span><br \/>Presentation Time\/Date: 1:50 \u2013 <span class=\"xn-chron\">2:20 p.m.<\/span> Eastern on <span class=\"xn-chron\">Tuesday, March 16, 2021<\/span><br \/>Format: Virtual conference; webcast available<\/li>\n<\/ul>\n<p>Webcasts of the H.C. Wainwright and Oppenheimer presentations may be accessed via a link on the Viking Therapeutics website in the Investors &amp; Media section under\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3086177-1&amp;h=2785723527&amp;u=http%3A%2F%2Fir.vikingtherapeutics.com%2Fwebcasts&amp;a=Webcasts\" rel=\"nofollow noopener noreferrer\">Webcasts<\/a>.\u00a0 Additionally, replays of the webcasts will be available on the Viking website following the conferences.\u00a0 <\/p>\n<p>\n        <b>About Viking Therapeutics, Inc. <\/b>\n      <\/p>\n<p>Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.\u00a0 Viking&#8217;s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients&#8217; lives.\u00a0 The company&#8217;s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase\u00a02b\u00a0study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.\u00a0 In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.\u00a0 The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).\u00a0 VK0214 is currently being evaluated in a Phase 1 first-in-human clinical trial.\u00a0 The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.<\/p>\n<p>For more information about Viking Therapeutics, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3086177-1&amp;h=3473960648&amp;u=http%3A%2F%2Fwww.vikingtherapeutics.com%2F&amp;a=www.vikingtherapeutics.com\" rel=\"nofollow noopener noreferrer\">www.vikingtherapeutics.com<\/a>. Follow Viking on Twitter @Viking_VKTX.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA98560&amp;sd=2021-03-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-301240245.html\">http:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-participate-at-upcoming-investor-conferences-301240245.html<\/a><\/p>\n<p>SOURCE  Viking Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA98560&amp;Transmission_Id=202103041630PR_NEWS_USPR_____LA98560&amp;DateId=20210304\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, March 4, 2021 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate in three upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: HC Wainwright Global Life Science ConferenceDetails: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference dates: March 9-10, 2021Presentation Timing: Available online at 7:00 a.m. Eastern on Tuesday, March 9, 2021Format: Virtual conference; webcast available 33rd Annual Roth ConferenceDetails: Viking management will participate in 1-on-1 meetingsConference Date: March 15-17, 2021\u00a0Format: Virtual Conference Oppenheimer&#8217;s 31st Annual Healthcare ConferenceDetails: Viking management will deliver a corporate presentation and participate in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viking Therapeutics to Participate at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451381","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, March 4, 2021 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate in three upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: HC Wainwright Global Life Science ConferenceDetails: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference dates: March 9-10, 2021Presentation Timing: Available online at 7:00 a.m. Eastern on Tuesday, March 9, 2021Format: Virtual conference; webcast available 33rd Annual Roth ConferenceDetails: Viking management will participate in 1-on-1 meetingsConference Date: March 15-17, 2021\u00a0Format: Virtual Conference Oppenheimer&#8217;s 31st Annual Healthcare ConferenceDetails: Viking management will deliver a corporate presentation and participate in &hellip; Continue reading &quot;Viking Therapeutics to Participate at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T21:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences\",\"datePublished\":\"2021-03-04T21:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\"},\"wordCount\":424,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\",\"name\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"datePublished\":\"2021-03-04T21:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics to Participate at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, March 4, 2021 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today\u00a0announced that the company will participate in three upcoming investor conferences.\u00a0 Details of the company&#8217;s participation are as follows: HC Wainwright Global Life Science ConferenceDetails: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference dates: March 9-10, 2021Presentation Timing: Available online at 7:00 a.m. Eastern on Tuesday, March 9, 2021Format: Virtual conference; webcast available 33rd Annual Roth ConferenceDetails: Viking management will participate in 1-on-1 meetingsConference Date: March 15-17, 2021\u00a0Format: Virtual Conference Oppenheimer&#8217;s 31st Annual Healthcare ConferenceDetails: Viking management will deliver a corporate presentation and participate in &hellip; Continue reading \"Viking Therapeutics to Participate at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T21:33:19+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viking Therapeutics to Participate at Upcoming Investor Conferences","datePublished":"2021-03-04T21:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/"},"wordCount":424,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/","name":"Viking Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","datePublished":"2021-03-04T21:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-participate-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics to Participate at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451381"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451381\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}